Neuroendocrine Tumors
Tumors whose cells possess secretory granules and originate from the neuroectoderm, i.e., the cells of the ectoblast or epiblast that program the neuroendocrine system. Common properties across most neuroendocrine tumors include ectopic hormone production (often via APUD CELLS), the presence of tumor-associated antigens, and isozyme composition.
Subtype terms (9)
More specific conditions that are subtypes of Neuroendocrine Tumors in the MeSH hierarchy.
- Adenoma, Acidophil
- Adenoma, Basophil
- Adenoma, Chromophobe
- Apudoma
1 drug approved
- Carcinoid Tumor
50 drugs (31 approved, 19 experimental)
- Carcinoma, Neuroendocrine
68 drugs (38 approved, 30 experimental)
- Melanoma
1301 drugs (311 approved, 990 experimental)
- Neurilemmoma
5 drugs (4 approved, 1 experimental)
- Paraganglioma
46 drugs (30 approved, 16 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (14)
Phase 3 trials (26)
- 131i-lipiodol
- 177lu-dota0-tyr3-octreotate
- 68ga-dotanoc
- atezolizumab
- doxorubicin
- fluorodopa
- gelatin
- in111-octreoscan
- mitomycin
- somatostatin
- sulfatinib
- bevacizumab
- furosemide
- cabozantinib
- iodized oil
- amino acids
- etoposide
- telotristat ethyl
- 131i-metaiodobenzylguanidine
- lutetium (177lu) oxodotreotide
- interferon alpha-2b
- toripalimab
- serotonin
- 18f-alf-nota-octreotide
- 177lu-dotatoc
- surufatinib
Phase 2 trials (120)
- retinoic acid
- 177lu-ops201
- F 18-fluoroazomycin arabinoside
- 18f-mfbg
- thalidomide
- 68ga-nota-ae105
- 90y-dota-tyr3-octreotide
- 124i-meta-iodobenzylguanidine
- abemaciclib
- advince
- axitinib
- oxytocin
- autologous tumor infiltrating lymphocytes
- avelumab
- olaparib
- sorafenib
- belinostat
- bi 754091
- carfilzomib
- temsirolimus
- cixutumumab
- mk-0646
- durvalumab
- entinostat
- entrectinib
- fosbretabulin
- ganitumab
- gemcitabine
- oblimersen sodium
- imatinib
- +90 more
Phase 1 trials (45)
- 177lu-pp-f11n
- 68ga-dota-jr11
- mkc1106
- blu-667
- talazoparib
- lenalidomide
- ly-2584702
- vincristine
- procaspase activating compound-1
- ifosfamide
- prostate specific membrane antigen
- seneca valley virus
- tirapazamine
- veliparib
- apg-1252
- black seed oil
- vatalanib
- trebananib
- iobenguane (123i)
- triprizumab
- pentixafor
- xmab18087
- 177lu-dota-eb-tate
- il13ralpha2-specific hinge-optimized 4-1bb-co-stimulatory car/truncated cd19-expressing autologous tn/mem cells (Biological)
- cedazuridine
- hbm4003
- elimusertib
- 3-[18f]fluoro-para-hydroxyphenethylguanidine
- 68ga-dota/nota-fapi-04
- [203pb]vmt-α-net
- +15 more
Organizations
Organization Involved with Phase 4 Indications (8)
Organization Involved with Phase 3 Indications (38)
- Genentech
- Sanofi
- ITM Solucin GmbH
- The Christie NHS Foundation Trust
- National Cancer Institute (NCI)
- University of Pennsylvania
- Baylor University
- Federation Francophone de Cancerologie Digestive
- Grupo Espanol de Tumores Neuroendocrinos (GETNE)
- Katholieke Universiteit Leuven
- McGill University
- Radio Isotope Therapy of America
- Southwest Oncology Group
- Utrecht University
- University of Alberta
- Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR)
- University of Calgary
- University of California, San Francisco
- University of Vienna
- Hutchison MediPharma
- RITA Foundation
- European Organisation for Research and Treatment of Cancer
- RadioMedix
- Pierrel Research
- University of Texas at Houston
- Free University of Brussels
- ABX-CRO
- University of Western Ontario
- NCM USA
- Aix-University of Marseille
- +8 more
Organization Involved with Phase 2 Indications (140)
- Molecular Insight Pharmaceuticals
- Eisai
- Celgene
- Bristol-Myers Squibb
- Amgen
- Roche
- Schering-Plough
- Merck
- Pharmacyclics
- Eli Lilly
- Exelixis
- Merck KGaA
- BTG
- Progenics
- AIO-Studien-gGmbH
- Arbutus Biopharma Corporation
- Bayer
- Camurus AB
- GlaxoSmithKline
- Hengrui Therapeutics, Inc.
- Ignyta, Inc.
- Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd
- Mateon Therapeutics
- Tarveda Therapeutics
- Threshold Pharmaceuticals
- Aadi, LLC
- Cylene Pharmaceuticals
- EpicentRx, Inc.
- TaiRx, Inc.
- Fundación de investigación HM
- +110 more
Organization Involved with Phase 1 Indications (26)
- AstraZeneca
- Blueprint Medicines Corporation
- Dicerna Pharmaceuticals, Inc.
- Esanex Inc.
- Provectus Biopharmaceuticals, Inc.
- Sichuan Huiyang Life Science and Technology Corporation
- Teclison Ltd.
- Otsuka
- PharmaMar
- Shanghai Junshi Bioscience Co.,Ltd.
- Vanquish Oncology, Inc.
- Vastra Gotaland Region
- National Cancer Institute, Milan
- Cancer Research UK
- Indiana University
- University of Kentucky
- University of Michigan
- Icahn School of Medicine at Mount Sinai
- Xencor
- National Taiwan University
- University of Illinois at Chicago
- ICON
- Medelis Inc.
- Orano
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
- NeuroEndocrine Tumor Research Foundation (NETRF)
Organization Involved with Other Experimental Indications (10)